Meeder Advisory Services Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 38,242 shares of the biopharmaceutical company’s stock after purchasing an additional 3,277 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Gilead Sciences were worth $5,700,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of GILD. BlackRock Inc. bought a new position in shares of Gilead Sciences in the second quarter worth about $15,393,785,000. State Street Corp boosted its stake in shares of Gilead Sciences by 2.3% in the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock valued at $7,734,099,000 after purchasing an additional 1,357,967 shares in the last quarter. Amundi boosted its stake in shares of Gilead Sciences by 10.7% in the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. Legal & General Group Plc bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $1,316,606,000. Finally, Boston Partners grew its holdings in shares of Gilead Sciences by 8.4% during the 3rd quarter. Boston Partners now owns 6,523,864 shares of the biopharmaceutical company’s stock valued at $970,367,000 after purchasing an additional 505,906 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.
Gilead Sciences Trading Down 0.1%
GILD opened at $166.33 on Friday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company’s 50 day moving average price is $157.26 and its two-hundred day moving average price is $142.46. The firm has a market capitalization of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.47 earnings per share. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.
Gilead Sciences Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.
Insider Buying and Selling
In other news, EVP Keeley Cain Wettan sold 3,399 shares of the stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the sale, the executive vice president owned 5,360 shares of the company’s stock, valued at approximately $879,629.60. This represents a 38.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $170.55, for a total value of $4,775,400.00. Following the completion of the transaction, the insider directly owned 110,684 shares in the company, valued at approximately $18,877,156.20. This represents a 20.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 237,709 shares of company stock worth $39,799,137. Corporate insiders own 0.30% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently commented on GILD shares. Scotiabank increased their price objective on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. UBS Group upped their price target on shares of Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $171.63.
View Our Latest Stock Report on Gilead Sciences
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Articles
- Five stocks we like better than Gilead Sciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
